NCCN Guidelines for Patients: Advanced-Stage Prostate Cancer, 2026 (2026)

Other · National Comprehensive Cancer Network (NCCN) · 2026

National Comprehensive Cancer Network (NCCN), 2026: NCCN's patient guide for advanced/metastatic prostate cancer places chemotherapy in the metastatic setting, naming docetaxel (Taxotere) as the most-used agent and stating it cannot cure but can extend life and reduce symptoms.

Docetaxel (Taxotere) is the chemotherapy medicine used most often to treat people with advanced prostate cancer. Although docetaxel can't cure prostate cancer, it can help people live longer while reducing pain and other symptoms.

34

National Comprehensive Cancer Network (NCCN), 2026: NCCN's patient guide for advanced/metastatic prostate cancer places chemotherapy in the metastatic setting, naming docetaxel (Taxotere) as the most-used agent and stating it cannot cure but can extend life and reduce symptoms. Funder: NCCN. Conflicts: not reproduced in patient version. Maker named on the page: Sanofi's brand Taxotere. Comparator: none stated in the patient text. Same page also lists cabazitaxel (Jevtana) and mitoxantrone (Novantrone).